Browse PPCS

Summary
SymbolPPCS
Namephosphopantothenoylcysteine synthetase
Aliases FLJ11838; PPC synthetase; Phosphopantothenate--cysteine ligase
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF04127 DNA / pantothenate metabolism flavoprotein
Function

Catalyzes the first step in the biosynthesis of coenzyme A from vitamin B5, where cysteine is conjugated to 4'-phosphopantothenate to form 4-phosphopantothenoylcysteine.

> Gene Ontology
 
Biological Process GO:0006164 purine nucleotide biosynthetic process
GO:0006732 coenzyme metabolic process
GO:0009108 coenzyme biosynthetic process
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009163 nucleoside biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0015936 coenzyme A metabolic process
GO:0015937 coenzyme A biosynthetic process
GO:0033865 nucleoside bisphosphate metabolic process
GO:0033866 nucleoside bisphosphate biosynthetic process
GO:0033875 ribonucleoside bisphosphate metabolic process
GO:0034030 ribonucleoside bisphosphate biosynthetic process
GO:0034032 purine nucleoside bisphosphate metabolic process
GO:0034033 purine nucleoside bisphosphate biosynthetic process
GO:0042278 purine nucleoside metabolic process
GO:0042451 purine nucleoside biosynthetic process
GO:0042455 ribonucleoside biosynthetic process
GO:0046128 purine ribonucleoside metabolic process
GO:0046129 purine ribonucleoside biosynthetic process
GO:0046390 ribose phosphate biosynthetic process
GO:0051186 cofactor metabolic process
GO:0051188 cofactor biosynthetic process
GO:0072522 purine-containing compound biosynthetic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1901657 glycosyl compound metabolic process
GO:1901659 glycosyl compound biosynthetic process
Molecular Function GO:0004632 phosphopantothenate--cysteine ligase activity
GO:0016874 ligase activity
GO:0016879 ligase activity, forming carbon-nitrogen bonds
GO:0016881 acid-amino acid ligase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00770 Pantothenate and CoA biosynthesis
hsa01100 Metabolic pathways
Reactome R-HSA-196783: Coenzyme A biosynthesis
R-HSA-1430728: Metabolism
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-196849: Metabolism of water-soluble vitamins and cofactors
R-HSA-199220: Vitamin B5 (pantothenate) metabolism
Summary
SymbolPPCS
Namephosphopantothenoylcysteine synthetase
Aliases FLJ11838; PPC synthetase; Phosphopantothenate--cysteine ligase
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PPCS and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPPCS
Namephosphopantothenoylcysteine synthetase
Aliases FLJ11838; PPC synthetase; Phosphopantothenate--cysteine ligase
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PPCS in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.09; FDR: 0.03410 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolPPCS
Namephosphopantothenoylcysteine synthetase
Aliases FLJ11838; PPC synthetase; Phosphopantothenate--cysteine ligase
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PPCS in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1520.414
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0780.973
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2110.895
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3280.2
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3550.831
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2970.892
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2560.475
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2780.855
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3140.86
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1520.935
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1110.97
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0940.171
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PPCS in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolPPCS
Namephosphopantothenoylcysteine synthetase
Aliases FLJ11838; PPC synthetase; Phosphopantothenate--cysteine ligase
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PPCS. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPPCS
Namephosphopantothenoylcysteine synthetase
Aliases FLJ11838; PPC synthetase; Phosphopantothenate--cysteine ligase
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PPCS. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PPCS.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPPCS
Namephosphopantothenoylcysteine synthetase
Aliases FLJ11838; PPC synthetase; Phosphopantothenate--cysteine ligase
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PPCS. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPPCS
Namephosphopantothenoylcysteine synthetase
Aliases FLJ11838; PPC synthetase; Phosphopantothenate--cysteine ligase
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PPCS expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPPCS
Namephosphopantothenoylcysteine synthetase
Aliases FLJ11838; PPC synthetase; Phosphopantothenate--cysteine ligase
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PPCS and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPPCS
Namephosphopantothenoylcysteine synthetase
Aliases FLJ11838; PPC synthetase; Phosphopantothenate--cysteine ligase
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PPCS collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.